A phase II study of gefitinib in patients with metastatic melanoma.

Sapna Pradyuman Patel,Kevin B. Kim,Nicholas E. Papadopoulos,Wen-Jen Hwu,Patrick Hwu,Victor G. Prieto,Menashe Bar-Eli,Maya Zigler,Andrey S. Dobroff,Yulia Bronstein,Roland L. Bassett,Anna Vardeleon,Agop Y. Bedikian

A phase II study of gefitinib in patients with metastatic melanoma.

2011

Sapna Pradyuman Patel
Kevin B. Kim
Nicholas E. Papadopoulos
Wen-Jen Hwu
Patrick Hwu
Victor G. Prieto
Menashe Bar-Eli
Maya Zigler
Andrey S. Dobroff
Yulia Bronstein
Roland L. Bassett
Anna Vardeleon
Agop Y. Bedikian

Background Gefitinib is an inhibitor of the epidermal growth factor receptor, which is frequently expressed on both choroidal and non-choroidal melanoma cells. We evaluated the clinical efficacy of gefitinib in patients with metastatic melanoma.

Keywords:

Phases of clinical research
Immunology
Choroid Neoplasm
Melanoma
Epidermal growth factor receptor
Young adult
Gefitinib
Pathology
Medicine
clinical efficacy
metastatic melanoma
in patient
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations